Botany
Pollination Biology of Fontainea picrosperma: Insect Vectors and Seed Set in the Blushwood Tree
Fontainea picrosperma is dioecious — male and female flowers occur on separate trees. Here is what is known about its pollinators and seed set.
Marcus Webb
Science writer and independent researcher specialising in natural compound pharmacology and translational oncology. Tracking EBC-46 (tigilanol tiglate) and Blushwood berry extract since 2019.
Human Trials
MRI as a Response Biomarker in Tigilanol Tiglate Clinical Trials
Imaging endpoints — particularly contrast-enhanced MRI — have become important in tigilanol tiglate trials. Here is how MRI is being used as a response biomarker.
Mechanism of Action
EBC-46 and Pattern Recognition Receptors: How Tigilanol Tiglate Engages Innate Immune Sensors
Tigilanol tiglate's mechanism extends beyond PKC activation. It engages innate immune pattern recognition receptors. Here is what the literature shows.
Regulatory
Singapore HSA Framework for Botanical Supplements: What It Means for EBC-46 Imports
Singapore's Health Sciences Authority regulates health supplements under a notification framework. Here is how that affects EBC-46 supplement category imports.
Consumer Reports / Supplement
With or Without Food: Pairing Meals with Blushwood Berry Extract EBC-46 Supplementation — User Reports
A neutral overview of how users describe pairing blushwood berry extract supplements with meals — fasted, with food, or with specific dietary fats — and how suppliers frame the question.
Natural Source / Botany
Leaf Phyllotaxis and Canopy Architecture in Fontainea picrosperma: Light Capture in the Blushwood Berry Tree
How alternate leaf arrangement, branch angles and rainforest understorey light shape canopy architecture in Fontainea picrosperma, the source of blushwood berries used in EBC-46 supplements.
Human Trials
Pharmacokinetic Monitoring in Tigilanol Tiglate Phase I Trials: EBC-46 Drug Metabolism Considerations
How pharmacokinetic sampling, plasma assays and exposure-response modelling are designed for intratumourally administered EBC-46 / tigilanol tiglate Phase I clinical trials.
Mechanism of Action
Pyroptosis and the Gasdermin Pathway: EBC-46, Tigilanol Tiglate and Inflammatory Cell Death
A neutral overview of pyroptosis — the gasdermin-mediated inflammatory form of cell death — and how it has been considered alongside other cell-death pathways linked to tigilanol tiglate.
Regulatory
Brazil ANVISA Classification of Botanical Supplements: EBC-46 and Blushwood Berry Considerations
How Brazil’s ANVISA classifies botanical food supplements under RDC 243/2018 and what this regulatory framework means for blushwood berry extract products.
consumer-reports
Morning vs. Evening Dosing of Blushwood Berry Extract: Patterns from User Reports
Users of blushwood berry extract supplements often ask whether morning or evening dosing makes a difference. Here is what observational reports describe and what is unknown.
natural-source
Mycorrhizal Associations of Fontainea picrosperma: Soil Biology Behind the Blushwood Berry
How arbuscular mycorrhizal fungi shape root nutrient uptake in tropical Euphorbiaceae like Fontainea picrosperma — and what this implies for blushwood cultivation.
Human Trials
Surrogate Endpoints in Tigilanol Tiglate Clinical Trials: Beyond Tumour Response Rate
Why oncology trials of intralesional tigilanol tiglate may benefit from surrogate endpoints — and which biomarkers are plausible candidates for future studies.